Compare UMBF & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UMBF | ARWR |
|---|---|---|
| Founded | 1913 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.6B |
| IPO Year | N/A | 1993 |
| Metric | UMBF | ARWR |
|---|---|---|
| Price | $119.24 | $68.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $136.27 | $60.70 |
| AVG Volume (30 Days) | 436.7K | ★ 3.3M |
| Earning Date | 01-27-2026 | 11-25-2025 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | ★ 10.98 | N/A |
| EPS | ★ 8.89 | N/A |
| Revenue | ★ $2,217,071,000.00 | $829,448,000.00 |
| Revenue This Year | $69.52 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | 45.52 | ★ 23258.15 |
| 52 Week Low | $82.00 | $9.57 |
| 52 Week High | $126.14 | $72.36 |
| Indicator | UMBF | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 65.02 | 72.80 |
| Support Level | $117.05 | $68.01 |
| Resistance Level | $120.58 | $72.36 |
| Average True Range (ATR) | 2.93 | 4.99 |
| MACD | 0.93 | 1.03 |
| Stochastic Oscillator | 87.52 | 86.66 |
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.